Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mimetogen Pharmaceuticals USA, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject-reported history of dry eye disease in both eyes for at least 6 months;
History of use of artificial tear eye drops for dry eye symptoms;
Total score of ≥40 on SANDE;
TFBUT;
Corneal fluorescein staining;
Lissamine green conjunctival staining;
Schirmer's test score.
You may not be if
Have participated in a previous tavilermide (MIM-D3) study;
Have clinically significant slit lamp findings at Visit 1;
Have a history of lacrimal duct obstruction within 12 months of Visit 1;
Have an uncontrolled systemic disease;
Be a woman who is pregnant, nursing or planning a pregnancy;
Be a woman of childbearing potential who is not using an acceptable means of birth control;
Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;
Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days prior to Visit 1.
Clareo Health | Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
